Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Denison Pharmaceuticals, LLC
WARNING LETTER
•Denison Pharmaceuticals, LLC•February 9, 2023

Denison Pharmaceuticals, LLC – FDA Warning Letter, Feb 9, 2023

Record Details

The FDA issued a Warning Letter to Denison Pharmaceuticals, LLC, following an inspection from January 5 to February 9, 2023, identifying significant Current Good Manufacturing Practice (CGMP) violations. The facility's drug products are deemed adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** Failure to thoroughly investigate lubricant contamination (non-food grade lubricant used for months, impacting over 60 batches including infant products), multiple foul odor complaints for a product (with TNTC yeast and mold, and *Staphylococcus epidermis* identified, yet deemed "fit for use" without market action), and numerous microbiological excursions in the purified water system (TNTC bacteria, lack of root cause, and impact assessment). 2. **Lack of Component Identity Testing (21 CFR 211.84(d)(1)):** Failure to test high-risk components like glycerin and propylene glycol for diethylene glycol (DEG) and ethylene glycol (EG) contamination, which can cause lethal poisoning. 3. **Unvalidated Test Methods (21 CFR 211.165(e)):** Failure to validate alternative rapid microbiological test methods, specifically the (b)(4) system, which showed failing results for total count and objectionable microorganisms (e.g

Company
Denison Pharmaceuticals, LLC
Inspection date
February 9, 2023
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations I
People
  • Lisa M. Harlan (Program Division Director)
  • Nancy M. Espinal (Investigator)
  • Keith Page
  • Micah S. Gerchenson
View Company Profile

ID · c2965870-94dc-43e6-b329-b059c7876903

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.84(d)(1)21 CFR 211.165(e)FD&C Act 501(a)(2)(B)FD&C Act 505(a)21.U.S.C. 355(a)FD&C Act 301

Full citation text and observation details available on the Dashboard.

Other documents for Denison Pharmaceuticals, LLC
  • 483 - 2025-08-26August 26, 2025
  • 483 - 2024-07-29July 29, 2024
  • 483 - 2023-02-09February 9, 2023
  • 483 - 2023-02-09February 9, 2023
  • 483 - 2017-10-25October 25, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Denison Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.